Baidu
map

CLIN CANCER RES:去甲基化治疗HPV相关头颈部肿瘤

2017-12-08 MedSci MedSci原创

在HPV相关头颈部鳞状细胞癌(HNSCC)中DNA甲基化对HPV肿瘤基因表达,肿瘤细胞增殖和生存具有重要意义。CLIN CANCER RES近期发表了一篇文章,研究DNA去甲基化药物5-aza在临床前模型中对HPV相关头颈部鳞状细胞癌的作用并探索其作为靶向疗法治疗HPV+HNSCC患者的可行性。

在HPV相关头颈部鳞状细胞癌(HNSCC)中DNA甲基化对HPV肿瘤基因表达,肿瘤细胞增殖和生存具有重要意义。CLIN CANCER RES近期发表了一篇文章,研究DNA去甲基化药物5-aza在临床前模型中对HPV相关头颈部鳞状细胞癌的作用并探索其作为靶向疗法治疗HPV+HNSCC患者的可行性。

作者使用HNSCC细胞系研究其对5-aza治疗的敏感性,使用异种移植鼠模型在体内研究5-aza活性。最后还分析了临床试验患者的肿瘤标本以鉴定5-aza治疗在HPV+HNSCC患者中的活性。临床试验及实验室数据表明5-aza可以诱导HPV+HNSCC肿瘤细胞生长抑制剂细胞凋亡。5-aza降低HPV基因表达,稳定p53基因,在HNSCC细胞和肿瘤中诱导p53依赖的细胞凋亡。5-aza抑制HPV+HNSCC基质金属蛋白酶(MMP)的表达和活性,在某些HPV+头颈部肿瘤细胞中活化IFN反应,在异种移植模型中抑制HPV+肿瘤侵入血管的能力。

文章最后认为,5-aza可以为HPV相关头颈部鳞状细胞肺癌提供有效的治疗,可以作为标准细胞毒疗法的替代选择。

原始出处:
Asel Biktasova,Michael Hajek,et al.Demethylation Therapy as a Targeted Treatment for Human Papillomavirus-Associated Head and Neck Cancer.CLIN CANCER RES.December 2017 doi:10.1158/1078-0432.CCR-17-1438

本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1735745, encodeId=eb1c1e357453e, content=<a href='/topic/show?id=9c363e259ba' target=_blank style='color:#2F92EE;'>#去甲基化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37259, encryptionId=9c363e259ba, topicName=去甲基化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=031d33977719, createdName=AspirantSuo, createdTime=Thu Nov 08 19:24:00 CST 2018, time=2018-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1491804, encodeId=315b149180403, content=<a href='/topic/show?id=b4f14442346' target=_blank style='color:#2F92EE;'>#头颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44423, encryptionId=b4f14442346, topicName=头颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b2d8903151, createdName=wshxjq, createdTime=Sun Dec 10 00:24:00 CST 2017, time=2017-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589740, encodeId=4c451589e4030, content=<a href='/topic/show?id=124d10065220' target=_blank style='color:#2F92EE;'>#颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100652, encryptionId=124d10065220, topicName=颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c46a17776631, createdName=木头人519, createdTime=Sun Dec 10 00:24:00 CST 2017, time=2017-12-10, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1735745, encodeId=eb1c1e357453e, content=<a href='/topic/show?id=9c363e259ba' target=_blank style='color:#2F92EE;'>#去甲基化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37259, encryptionId=9c363e259ba, topicName=去甲基化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=031d33977719, createdName=AspirantSuo, createdTime=Thu Nov 08 19:24:00 CST 2018, time=2018-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1491804, encodeId=315b149180403, content=<a href='/topic/show?id=b4f14442346' target=_blank style='color:#2F92EE;'>#头颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44423, encryptionId=b4f14442346, topicName=头颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b2d8903151, createdName=wshxjq, createdTime=Sun Dec 10 00:24:00 CST 2017, time=2017-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589740, encodeId=4c451589e4030, content=<a href='/topic/show?id=124d10065220' target=_blank style='color:#2F92EE;'>#颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100652, encryptionId=124d10065220, topicName=颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c46a17776631, createdName=木头人519, createdTime=Sun Dec 10 00:24:00 CST 2017, time=2017-12-10, status=1, ipAttribution=)]
    2017-12-10 wshxjq
  3. [GetPortalCommentsPageByObjectIdResponse(id=1735745, encodeId=eb1c1e357453e, content=<a href='/topic/show?id=9c363e259ba' target=_blank style='color:#2F92EE;'>#去甲基化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37259, encryptionId=9c363e259ba, topicName=去甲基化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=031d33977719, createdName=AspirantSuo, createdTime=Thu Nov 08 19:24:00 CST 2018, time=2018-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1491804, encodeId=315b149180403, content=<a href='/topic/show?id=b4f14442346' target=_blank style='color:#2F92EE;'>#头颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44423, encryptionId=b4f14442346, topicName=头颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b2d8903151, createdName=wshxjq, createdTime=Sun Dec 10 00:24:00 CST 2017, time=2017-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589740, encodeId=4c451589e4030, content=<a href='/topic/show?id=124d10065220' target=_blank style='color:#2F92EE;'>#颈部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100652, encryptionId=124d10065220, topicName=颈部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c46a17776631, createdName=木头人519, createdTime=Sun Dec 10 00:24:00 CST 2017, time=2017-12-10, status=1, ipAttribution=)]

相关资讯

ANN ONCOL:酒精和烟草摄入可以预测头颈部肿瘤患者死亡率

ANN ONCOL近期发表了一篇文章,研究人口特征,诊断前生活习惯和临床数据是否与头颈部肿瘤患者总生存和头颈部肿瘤特异性生存有关。

CLIN CANCER RES:头颈部肿瘤中人乳头瘤病毒调节HER3表达

人乳头瘤病毒(HPV)16在头颈部鳞状细胞癌(HNSCC)中具有病因学作用,同时病毒表达的E6和E7癌蛋白是肿瘤生长所必须的物质。HPV+肿瘤患者预后更好,但是目前尚缺乏HPV特异性治疗方式。近期研究发现HPV+肿瘤与HPV-肿瘤受体络氨酸激酶(RTK)不同。HER3就是这些RTK中的一种,HER3在HPV+肿瘤中高表达且与PI3K作用。CLIN CANCER RES近期发表了一篇文章,研究HPV

CLIN CANCER RES:SMAD4缺失与头颈部肿瘤细胞西妥昔单抗耐药和MAPK/JNK活化有关

已有研究证实了SMAD4表达下调与头颈部鳞状细胞癌(HNSCC)西妥昔单抗耐药有关。CLIN CANCER RES近期发表了一篇文章,进一步阐明头颈部鳞状细胞癌SMAD4缺失的临床意义。

CLIN CANCER RES:头颈部肿瘤患者血浆外泌体抑制淋巴细胞功能

头颈部肿瘤通常会诱导产生强力的免疫抑制,有助于疾病进展并影响免疫治疗的疗效。头颈部肿瘤患者的血液中外泌体含量升高,会对抗肿瘤反应产生负向影响。CLIN CANCER RES近期发表了一篇文章,研究头颈部肿瘤患者血浆中外泌体含量,并评估其对免疫功能紊乱及疾病活性的影响。

BJC:叶酸摄入与头颈部肿瘤风险

低水平叶酸会导致DNA复制、DNA甲基化和DNA修复障碍,但是饮食叶酸摄入与头颈部肿瘤风险之间的关系尚不清楚。BJC近期发表了一篇文章研究这一问题。

2016NCCN临床实践指南——头颈部肿瘤-极晚期头颈部肿瘤-证据块(2016.V2)发布

英文标题:NCCN Clinical Practice Guidelines in Oncology:Head and Neck Cancers:Very Advanced Head and Neck Cancer-NCCN Evidence Blocks(Version 2.2016)发布机构:美国国家综合癌症网络(NCCN,National Comprehensive Cancer Netwo

Baidu
map
Baidu
map
Baidu
map